Leo Pharma poised to market new drug every 2-3 years

Dermatology company Leo Pharma turns its eyes towards 2030 with a new strategy to help cement the group’s position on the skin disease treatment market and to firmly position the company in the US.
Leo Pharma CEO Catherine Mazzacco ays the company's own labs will produce more drug candidates in the following years. | Photo: Leo Pharma / PR
Leo Pharma CEO Catherine Mazzacco ays the company's own labs will produce more drug candidates in the following years. | Photo: Leo Pharma / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Leo Pharma hits the speeder as the company now plans to shower the market with new treatments for both rare and more common skin diseases.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading